- Home
- LUCY vs NXL Comparison
LUCY vs NXL Comparison
Compare LUCY & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCY | NXL |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 7.5M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LUCY | NXL |
|---|---|---|
| Price | $0.83 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 114.5K | 54.7K |
| Earning Date | 11-20-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.39 | 39.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,661,669.00 | $301,647.00 |
| Revenue This Year | $170.51 | $14.37 |
| Revenue Next Year | $205.56 | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 62.65 | ★ 78.78 |
| 52 Week Low | $0.65 | $0.22 |
| 52 Week High | $2.02 | $81.60 |
Technical Indicators
Market Signals| Indicator | LUCY | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 27.94 |
| Support Level | $0.78 | $0.22 |
| Resistance Level | $0.89 | $5.36 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | -0.00 | 0.13 |
| Stochastic Oscillator | 52.01 | 7.42 |
Price Performance
Historical ComparisonAbout LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok. The firm derive substantially all of its revenue from the sale of smart glasses and custom lenses.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.